Skip to content

Clinical trials

Multiple Sclerosis, Relapsing-Remitting trials in France with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Phase: Not applicable Country / region: France Clear all

16 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20121
20131
20141
20172
20193
20202
20221
20231
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Not yet recruiting2
Active, not recruiting1
Recruiting1
Terminated1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institut National de la Santé Et de la Recherche Médicale, France2
Nantes University Hospital2
University Hospital, Caen2
University Hospital, Montpellier2
Assistance Publique - Hôpitaux de Paris1
Centre Hospitalier Universitaire de Nīmes1
Institut Pasteur1
Rennes University Hospital1
Réseau Sep Idf Ouest1
University Hospital, Bordeaux1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis, Relapsing-Remitting16
Multiple Sclerosis8
Multiple Sclerosis, Chronic Progressive5
Cognitive Dysfunction2
Nervous System Diseases2
Autoimmune Diseases1
Autoimmune Diseases of the Nervous System1
Conversion Disorder1
Demyelinating Autoimmune Diseases, CNS1
Demyelinating Diseases1

Trials

Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.